Switzerland-based Novartis has received breakthrough therapy designation from the US Food and Drug Administration (FDA) for crizanlizumab (SEG101) in order to prevent vaso-occlusive crises in patients of all genotypes with sickle cell disease, it was reported yesterday.
The product is a humanised anti-P-selectin monoclonal antibody being studied to restrict vaso-occlusive crises in sickle cell disease.
The status has been offered based on positive data from the phase II Sustain study, which compared the P-selectin inhibitor crizanlizumab against placebo in patients with sickle cell disease. The study indicated that crizanlizumab decreased the median annual rate of vaso-occlusive crises leading to health care visits by 45.3% compared to placebo in patients with or without hydroxyurea therapy, according to the company. The sustain study also showed that crizanlizumab significantly increased the percentage of patients who did not experience any vaso-occlusive crises against placebo during treatment.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT